CREATE YOUR MyTHERAKOS ACCOUNT

By registering with MyTHERAKOS, you can take advantage of our event calendar, keep up to date with upcoming webinars and watch those you missed on demand.

If you have a CELLEX^TM system, you will also have exclusive access to the E-Learning platform and a dashboard where you can see the status of your orders, operator manuals, technical bulletins and much more.

Registration to MyTHERAKOS is for healthcare professionals only and is not intended for use in the US and Canada.

WHAT’S AVAILABLE IN YOUR MyTHERAKOS ACCOUNT AREA

Live and on-demand webinars, from experienced key opinion leaders. Register for upcoming webinars and quickly review webinars you've already attended.

MEMBER EVENTS

We're more than webinars. The Therakos Institute hosts symposia, centres of excellence, meet and ask the expert sessions. By creating your MyTHERAKOS account, you can access everything easily.

GAIN ACCESS TO EXCLUSIVE CONTENT

We're continually updating content available within MyTHERAKOS, available to any HCP looking to learn more about ECP.

IF YOU HAVE A CELLEX™ PHOTOPHERSIS SYSTEM IN YOUR HEALTHCARE FACILITY, YOU'LL ALSO SEE:

MANAGEMENT DASHBOARD

Handle everything around your system orders in one simple place including service requests and invoices.

E-LEARNING - OPERATOR RESOURCES

Training and materials to operate your CELLEX^TM System.

RESOURCE LIBRARY

Our operators resources include reference guides, technical bulletins, training materials and user manuals.

TO CREATE YOUR PROFILE, PLEASE COMPLETE THE FORM BELOW.

Title

*Name

*Surname

*Email

*Repeat Email

*Role/Specialty

Some areas of our site are restricted from the public. Inputing your role will help ensure you are able to view all content relevant to you.

*Country of work

By inputting your country, we can better ensure you are getting access to the content most relevant to you. If you are also an existing customer and have inputted your CELLEX^TM System serial number, the CELLEX^TM training materials will be available in your local language.

*Institution/Hospital/Place of work

Some areas of our site are restricted from the public and from certain regions. Inputing your institution will help ensure you are able to view all content relevant to you.

*Preferred language for communications

PLEASE SELECT AT LEAST ONE OF THE SERVICES BELOW YOU WOULD LIKE TO GET ACCESS TO

*Would you like to sign-up for our Therakos Institute webinars?

Yes No

*Do you have a CELLEX device?

If you are an existing customer/user, you can also sign up for MyTherakos.

Yes No

*Please insert your CELLEX^TM System serial number

Required to gain access to CELLEX^TM System training and support materials. Your serial number can be found on your instrument.

The serial number can be found on your device

Would you like to be informed via email about all our upcoming events?

Yes No

If you would like to learn more about how we collect and manage your data please refer to our privacy policy

*Compulsory fields

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

CREATE YOUR MyTHERAKOS ACCOUNT

WHAT’S AVAILABLE IN YOUR MyTHERAKOS ACCOUNT AREA

MEMBER EVENTS

GAIN ACCESS TO EXCLUSIVE CONTENT

IF YOU HAVE A CELLEX™ PHOTOPHERSIS SYSTEM IN YOUR HEALTHCARE FACILITY, YOU'LL ALSO SEE:

MANAGEMENT DASHBOARD

E-LEARNING - OPERATOR RESOURCES

RESOURCE LIBRARY

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS